|
May 13
|
Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?
|
|
May 13
|
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
|
|
May 13
|
MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD
|
|
May 12
|
London stocks strike month-high after US-China tariff deal
|
|
May 12
|
Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower
|
|
May 12
|
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
|
|
May 12
|
AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial
|
|
May 12
|
Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices
|
|
May 12
|
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices
|
|
May 10
|
AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer
|
|
Apr 22
|
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial
|
|
Apr 21
|
Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...
|
|
Apr 21
|
AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial
|
|
Apr 21
|
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
|
|
Apr 21
|
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
|
|
Apr 21
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
|
|
Apr 17
|
Six FTSE 100 stock ideas for the second quarter, according to Barclays
|
|
Feb 15
|
AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
|
|
Feb 15
|
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
|
|
Feb 14
|
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
|